These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21568291)

  • 1. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
    Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
    J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.
    Koike T; Hoashi Y; Takai T; Nakayama M; Yukuhiro N; Ishikawa T; Hirai K; Uchikawa O
    J Med Chem; 2011 May; 54(9):3436-44. PubMed ID: 21473625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
    Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
    J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
    Attia MI; Witt-Enderby PA; Julius J
    Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.
    Carocci A; Catalano A; Lovece A; Lentini G; Duranti A; Lucini V; Pannacci M; Scaglione F; Franchini C
    Bioorg Med Chem; 2010 Sep; 18(17):6496-511. PubMed ID: 20674373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
    J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
    Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
    Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, NMR conformational analysis and pharmacological evaluation of 7,7a,13,14-tetrahydro-6H-cyclobuta[b]pyrimido[1,2-a:3,4-a']diindole analogues as melatonin receptor ligands.
    Attia MI; Güclü D; Hertlein B; Julius J; Witt-Enderby PA; Zlotos DP
    Org Biomol Chem; 2007 Jul; 5(13):2129-37. PubMed ID: 17581657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
    Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
    Duplantier AJ; Bachert EL; Cheng JB; Cohan VL; Jenkinson TH; Kraus KG; McKechney MW; Pillar JD; Watson JW
    J Med Chem; 2007 Jan; 50(2):344-9. PubMed ID: 17228876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
    Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
    J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism-based identification of a potent thrombin receptor antagonist.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee W; Kao G; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Smith-Torhan A; Alton K; Bryant M; Hsieh Y; Lau J; Palamanda J
    J Med Chem; 2007 Jan; 50(1):129-38. PubMed ID: 17201416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist.
    Hoashi Y; Takai T; Kosugi Y; Nakashima M; Nakayama M; Hirai K; Uchikawa O; Koike T
    J Med Chem; 2021 Mar; 64(6):3059-3074. PubMed ID: 33682410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
    Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
    J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) -selectivity.
    Markl C; Clafshenkel WP; Attia MI; Sethi S; Witt-Enderby PA; Zlotos DP
    Arch Pharm (Weinheim); 2011 Oct; 344(10):666-74. PubMed ID: 21887801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
    Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.